Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune effects of bevacizumab: killing two birds with one stone.

Literature DB >> 25326055

Immune effects of bevacizumab: killing two birds with one stone.

Yasir Y Elamin¹, Shereen Rafee, Sinead Toomey, Bryan T Hennessy.

Abstract

Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial growth factor-A (VEGF-A) - a key molecular player inangiogenesis. Bevacizumumab has shown clinical efficacy in phase III clinical trials inseveral advanced solid malignancies. The clinical efficacy of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing the immune system to restore itsantitumour activity has been utilized successfully in clinical setting. In this article we willdiscuss the possible immunomodulatory effects of the most clinically usedantiangiogenic agent; bevacizumumab.

Entities: Chemical Disease Gene

Year: 2014 PMID： 25326055 PMCID： PMC4449343 DOI： 10.1007/s12307-014-0160-8

Source DB: PubMed Journal: Cancer Microenviron ISSN： 1875-2284

63 in total

1. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors: Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal: Circ Res Date: 2010-06-10 Impact factor: 17.367

2. A phase 3 trial of bevacizumab in ovarian cancer.

Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245

3. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells.

Authors: Tae-Hee Lee; Hava Avraham; Seung-Hoon Lee; Shalom Avraham
Journal: J Biol Chem Date: 2002-01-09 Impact factor: 5.157

4. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.

Authors: Kousaku Mimura; Koji Kono; Akihiro Takahashi; Yoshihiko Kawaguchi; Hideki Fujii
Journal: Cancer Immunol Immunother Date: 2006-11-04 Impact factor: 6.968

5. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.

Authors: F Samaniego; P D Markham; R Gendelman; Y Watanabe; V Kao; K Kowalski; J A Sonnabend; A Pintus; R C Gallo; B Ensoli
Journal: Am J Pathol Date: 1998-06 Impact factor: 4.307

6. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Authors: Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken
Journal: PLoS One Date: 2009-11-03 Impact factor: 3.240

7. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson
Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544

8. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544

Review 9. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Authors: A Valachis; N P Polyzos; N Alpha Patsopoulos; V Georgoulias; D Mavroudis; D Mauri
Journal: Breast Cancer Res Treat Date: 2010-01-09 Impact factor: 4.872

10. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Authors: Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse
Journal: Cancer Immunol Immunother Date: 2008-01-10 Impact factor: 6.968

16 in total

1. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.

Authors: Wenxin Xu; Maneka Puligandla; Judith Manola; Andrea J Bullock; Daniel Tamasauskas; David F McDermott; Michael B Atkins; Naomi B Haas; Keith Flaherty; Robert G Uzzo; Janice P Dutcher; Robert S DiPaola; Rupal S Bhatt
Journal: Clin Cancer Res Date: 2019-08-30 Impact factor: 12.531

Review 2. Anti-angiogenic agents in metastatic colorectal cancer.

Authors: Bhavana Konda; Helen Shum; Lakshmi Rajdev
Journal: World J Gastrointest Oncol Date: 2015-07-15

3. Tumor-Infiltrating Lymphocytes and Colorectal Cancer Survival in African American and Caucasian Patients.

Authors: Kristin Wallace; David N Lewin; Shaoli Sun; Clayton M Spiceland; Don C Rockey; Alexander V Alekseyenko; Jennifer D Wu; John A Baron; Anthony J Alberg; Elizabeth G Hill
Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254

4. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Authors: Daniel P Petrylak; Ronald de Wit; Kim N Chi; Alexandra Drakaki; Cora N Sternberg; Hiroyuki Nishiyama; Daniel Castellano; Syed A Hussain; Aude Fléchon; Aristotelis Bamias; Evan Y Yu; Michiel S van der Heijden; Nobuaki Matsubara; Boris Alekseev; Andrea Necchi; Lajos Géczi; Yen-Chuan Ou; Hasan Senol Coskun; Wen-Pin Su; Jens Bedke; Georgios Gakis; Ivor J Percent; Jae-Lyun Lee; Marcello Tucci; Andrey Semenov; Fredrik Laestadius; Avivit Peer; Giampaolo Tortora; Sufia Safina; Xavier Garcia Del Muro; Alejo Rodriguez-Vida; Irfan Cicin; Hakan Harputluoglu; Scott T Tagawa; Ulka Vaishampayan; Jeanny B Aragon-Ching; Oday Hamid; Astra M Liepa; Sameera Wijayawardana; Francesca Russo; Richard A Walgren; Annamaria H Zimmermann; Rebecca R Hozak; Katherine M Bell-McGuinn; Thomas Powles
Journal: Lancet Oncol Date: 2019-11-18 Impact factor: 41.316

5. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

Authors: David F McDermott; Mahrukh A Huseni; Michael B Atkins; Robert J Motzer; Brian I Rini; Bernard Escudier; Lawrence Fong; Richard W Joseph; Sumanta K Pal; James A Reeves; Mario Sznol; John Hainsworth; W Kimryn Rathmell; Walter M Stadler; Thomas Hutson; Martin E Gore; Alain Ravaud; Sergio Bracarda; Cristina Suárez; Riccardo Danielli; Viktor Gruenwald; Toni K Choueiri; Dorothee Nickles; Suchit Jhunjhunwala; Elisabeth Piault-Louis; Alpa Thobhani; Jiaheng Qiu; Daniel S Chen; Priti S Hegde; Christina Schiff; Gregg D Fine; Thomas Powles
Journal: Nat Med Date: 2018-06-04 Impact factor: 53.440

Review 6. Immunotherapy Updates in Advanced Hepatocellular Carcinoma.

Authors: Amisha Singh; Ryan J Beechinor; Jasmine C Huynh; Daneng Li; Farshid Dayyani; Jennifer B Valerin; Andrew Hendifar; Jun Gong; May Cho
Journal: Cancers (Basel) Date: 2021-04-30 Impact factor: 6.639

Review 7. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.

Authors: Kanawat Wiwatchaitawee; Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal: AAPS PharmSciTech Date: 2021-02-11 Impact factor: 4.026

Review 8. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.

Authors: Assia Angelova; Jean Rommelaere
Journal: Viruses Date: 2019-05-04 Impact factor: 5.048

Review 9. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.

Authors: Letizia Procaccio; Vera Damuzzo; Francesca Di Sarra; Alberto Russi; Federica Todino; Vincenzo Dadduzio; Francesca Bergamo; Alessandra Anna Prete; Sara Lonardi; Hans Prenen; Angelo Claudio Palozzo; Fotios Loupakis
Journal: Drug Saf Date: 2019-02 Impact factor: 5.228

10. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Authors: Alan Mackay; Anna Burford; Valeria Molinari; David T W Jones; Elisa Izquierdo; Jurriaan Brouwer-Visser; Felice Giangaspero; Christine Haberler; Torsten Pietsch; Thomas S Jacques; Dominique Figarella-Branger; Daniel Rodriguez; Paul S Morgan; Pichai Raman; Angela J Waanders; Adam C Resnick; Maura Massimino; Maria Luisa Garrè; Helen Smith; David Capper; Stefan M Pfister; Thomas Würdinger; Rachel Tam; Josep Garcia; Meghna Das Thakur; Gilles Vassal; Jacques Grill; Tim Jaspan; Pascale Varlet; Chris Jones
Journal: Cancer Cell Date: 2018-05-14 Impact factor: 31.743